Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | PRNP | P04156 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309241 | 1.00 | NQO2 (0.39) | NQO2LMNAHPGDALDH1A1APOBEC3G | |
| SCHEMBL15195547 | 0.83 | NQO2 (0.33) | NQO2LMNAHPGDALDH1A1NPSR1 | |
| SCHEMBL20361147 | 0.83 | LMNA (0.37) | NQO2LMNAHPGDALDH1A1APOBEC3G | |
| SCHEMBL30631413 | 0.83 | NQO2 (0.33) | NQO2LMNAHPGDALDH1A1NPSR1 | |
| SCHEMBL17408873 | 0.83 | ALDH1A1 (0.37) | NQO2LMNAHPGDALDH1A1APOBEC3G | |
| SCHEMBL2258481 | 0.81 | NQO2 (0.46) | NQO2LMNAHPGDALDH1A1APOBEC3G | |
| SCHEMBL19068130 | 0.79 | HPGD (0.48) | NQO2LMNAHPGDALDH1A1NPSR1 | |
| SCHEMBL16797274 | 0.79 | POLB (0.34) | NQO2LMNAHPGDALDH1A1APOBEC3G | |
| SCHEMBL1558796 | 0.79 | LMNA (0.39) | NQO2LMNAHPGDALDH1A1APOBEC3G | |
| SCHEMBL15972382 | 0.79 | KEAP1 (0.38) | NQO2LMNAHPGDALDH1A1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BEONE MEDICINES I GMBH (CH) | 2026-03-24 | — | — | US | disclosed |
| CN-118047654-A | Process for preparing aryl halides starting from aromatic amines | 黑龙江立科新材料有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
| CN-115916790-A | Pyrido [2,3-b ] [1,4] oxazines or tetrahydropyrido [2,3-b ] [1,4] oxazepines as IAP antagonists | 百济神州有限公司 | 2023-04-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BIRC2, BIRC3, BIRC5 | NQO2 3709/4885LMNA 810/4885HPGD 2583/4885 |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BIRC2, BIRC3, API5 | NQO2 2476/4885LMNA 738/4885HPGD 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.